{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-26-000054","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2026-05-11T20:11:38+00:00","discovered_at":"2026-05-11T20:13:00.402887+00:00","generated_at":"2026-05-11T20:16:24.229240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SI-BONE Q1 revenue $52.6M (+11%), net loss improves 33.8%; raises FY26 guidance","bullets":["Worldwide revenue $52.6M (+11.2% YoY); US revenue $49.3M (+10.0%), international $3.3M (+33.9%).","Net loss $4.3M (-33.8% YoY, -$0.10 diluted EPS); adjusted EBITDA $2.5M (vs $0.5M, >440% improvement).","Gross margin stable at 79.8%; operating loss improved 31.9% to $5.1M.","Raised FY2026 revenue guidance to $230-233M (prior $228.5-232.5M); gross margin ~79% (prior ~78%).","Operational: over 1,650 active US physicians (+17%); CMS proposes new MS-DRG for complex spinal fusion with iFuse Bedrock Granite."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-26-000054","json":"https://secwatch.observer/filing/0001459839-26-000054.json","markdown":"https://secwatch.observer/filing/0001459839-26-000054.md","text":"https://secwatch.observer/filing/0001459839-26-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/0001459839-26-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/sibn-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T20:16:24.229240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49e971d2e379b05f9b945277ea5d5e71a2aea109","claim":"SI-BONE, Inc. reported quarter ended March 31, 2026 results: revenue $52.6 million, net income $4.3 million, EPS $0.10 per diluted share. Guidance raised.","evidence_excerpt":"physician engagement and ~440% improvement in adjusted EBITDA First Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $52.6 million, representing growth of 11.2% • U.S. revenue of $49.3 million, representing growth of 10.0% • Gross margin of 79.8% • Net loss of $4.3 million, representing an improvement of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1459839/000145983926000054/0001459839-26-000054-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"$52.6 million"},{"label":"Net income","value":"$4.3 million"},{"label":"EPS","value":"$0.10 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}